Stoke Therapeutics (STOK) Operating Margin: 2022-2025
Historic Operating Margin for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -405.30%.
- Stoke Therapeutics' Operating Margin rose 20776.00% to -405.30% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.23%, marking a year-over-year increase of 71383.00%. This contributed to the annual value of -277.31% for FY2024, which is 102990.00% up from last year.
- Per Stoke Therapeutics' latest filing, its Operating Margin stood at -405.30% for Q3 2025, which was down 105.13% from -197.58% recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Operating Margin registered a high of 70.15% during Q1 2025, and its lowest value of -1,340.67% during Q2 2023.
- For the 3-year period, Stoke Therapeutics' Operating Margin averaged around -562.32%, with its median value being -607.37% (2024).
- Per our database at Business Quant, Stoke Therapeutics' Operating Margin crashed by 55,955bps in 2023 and then surged by 99,551bps in 2024.
- Stoke Therapeutics' Operating Margin (Quarterly) stood at -831.58% in 2022, then slumped by 22,431bps to -1,055.89% in 2023, then surged by 99,551bps to -60.37% in 2024, then skyrocketed by 20,776bps to -405.30% in 2025.
- Its Operating Margin was -405.30% in Q3 2025, compared to -197.58% in Q2 2025 and 70.15% in Q1 2025.